TB-500, the questions people actually ask — answered from the literature.

TB-500 Side Effects and Safety Signals in Research

The honest headline on TB-500 side effects is that the fragment has no characterized human side-effect profile. The only controlled human safety data are for full-length thymosin beta-4: an intravenous Phase 1 study found it well tolerated to 1260 mg with only infrequent mild or moderate events and no serious adverse events ^[6]. That is a clean read — on a different molecule, by a supervised route.

The safety signal the literature does flag is biological, not anecdotal. Thymosin beta-4 is overexpressed in several cancers and is implicated in metastasis and tumor angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair raise a theoretical oncologic concern ^[10]. Add the unresolved identity and purity of research-grade material, and the result is a compound with real open questions that a 2026 review describes as operating largely outside regulatory oversight ^[10]. The questions below answer the rest, one bubble at a time.

TB-500 and BPC-157 in Recovery Research

TB-500 and BPC-157 are constantly paired in recovery discussion, but they are distinct molecules with distinct proposed mechanisms. TB-500 is the synthetic Ac-LKKTETQ fragment of thymosin beta-4 acting through actin sequestration ^[1]; BPC-157 is a separate gastric-derived peptide with a different proposed mechanism. Both are unapproved research peptides studied for tissue repair in animal models, and the 2026 sports-medicine review lists them together among unapproved peptides with favorable animal data but scarce human safety evidence ^[10]. No combined protocol has been validated in controlled human trials — pairing them is a community practice, not a studied one.

Does TB-500 have neuroprotective effects on the brain?

In rodent stroke and traumatic-brain-injury models, full-length thymosin beta-4 improved neurological recovery ^[4][7], and a 2024 zebrafish study showed enhanced axon regeneration via actin dynamics ^[11]. These are preclinical findings, mostly with the full-length protein rather than the TB-500 heptapeptide, and none are human efficacy data. The deeper read is on TB-500 neuroprotection and neurological recovery research.

What dose of thymosin beta-4 was used in stroke studies?

In a rat embolic-stroke dose-response study, intraperitoneal thymosin beta-4 was given at 2, 12, and 18 mg/kg starting 24 hours post-stroke, then every three days for four more doses; the 2 and 12 mg/kg arms improved neurological function while 18 mg/kg did not, and a modeled optimal dose near ~3.75 mg/kg was proposed ^[4].

What is TB-500?

TB-500 is the synthetic N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17 to 23 — the actin-binding motif — of the 43-amino-acid protein thymosin beta-4 ^[1]. It is supplied for research and veterinary contexts and has no approved human therapeutic indication. The parent protein is the body's principal G-actin-sequestering peptide ^[5].

What does TB-500 stand for and what does TB stand for in TB-500?

TB refers to thymosin beta. TB-500 is a research and veterinary designation for the synthetic Ac-LKKTETQ fragment of thymosin beta-4 — the parent protein is itself abbreviated Tβ4 ^[1]. The "500" is a product-style identifier, not a measure of dose, mass, or potency.

What is TB-500 used for in research?

Thymosin beta-4 and its actin-binding region have been studied in animal and topical-human models for wound healing, soft-tissue and ligament repair, cardiac protection, angiogenesis, anti-fibrotic remodeling, and neurological recovery ^[5]. Efficacy of the isolated heptapeptide in humans is unproven, and a 2026 review classes it among unapproved peptides with scarce human data ^[10].

Does TB-500 work for muscle tears and recovery from exercise?

Injury-induced thymosin beta-4 acts as a myoblast chemoattractant in animal models, and a 2026 sports-medicine review lists TB-500 among unapproved recovery peptides with favorable animal repair data but scarce human safety evidence ^[10]. A muscular-dystrophy mouse study found more regenerating fibers without gains in muscle strength — "more regeneration" did not equal "more function".

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is overexpressed in several cancers and has been implicated in metastasis and tumor angiogenesis, so its pro-migratory, pro-angiogenic properties raise a theoretical oncologic concern ^[10]. This is a flagged safety signal, not a demonstrated human risk for the TB-500 fragment. The same activity also underlies its repair effects, which is why the concern is mechanistic rather than observed.

Is TB-500 banned by WADA and in competitive sports?

Yes. TB-500 and thymosin beta-4 fall under the World Anti-Doping Agency's prohibited peptide/growth-factor and tissue-repair categories, banned in and out of competition for the relevant classes, and are detectable by LC-MS anti-doping assays in equine and human matrices ^[10]. The detection science is mature precisely because the substance has been a doping-control target.

Is TB-500 FDA approved?

No. TB-500 is not approved by the FDA for human use and has no approved therapeutic indication ^[16]. FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — bulk substances that may present significant safety risks — meaning it is also not within FDA's enforcement-discretion policy for compounding ^[16][18].

Are there any human clinical trials on TB-500?

No completed controlled clinical trials of the TB-500 heptapeptide exist for any indication ^[10]. Human data are limited to full-length thymosin beta-4: a randomized, placebo-controlled Phase 1 intravenous safety study in healthy volunteers ^[6], and topical ophthalmic (RGN-259) dry-eye and corneal-healing trials ^[9].

How does TB-500 work?

TB-500 carries thymosin beta-4's WH2-type actin-binding motif. The parent protein sequesters monomeric G-actin one-to-one and caps both ends of the monomer, regulating cytoskeletal dynamics, cell migration, angiogenesis, and survival signaling ^[1]. Whether the isolated 7-mer reproduces these effects at research doses is not established in controlled human trials ^[10].

How long does it take for TB-500 to work for injury healing?

Timelines come only from animal models, not human trials. In a rat full-thickness wound study, thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline ^[3]. No validated human healing timeline exists for the fragment ^[10].

Can TB-500 help with tendon injuries and ligament repair?

The connective-tissue rationale rests on thymosin beta-4's documented roles in cell migration, angiogenesis, and reduced scarring across animal repair models ^[5]. These are animal results; controlled human tendon or ligament data for TB-500 are not available, and the 2026 review classes it among unapproved recovery peptides with scarce human evidence ^[10].

Does TB-500 affect the heart?

In mice, thymosin beta-4 activated the PINCH-ILK-Akt survival pathway and, after coronary artery ligation, enhanced early cardiomyocyte survival and improved cardiac function ^[2]. Counter-evidence exists — systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study — so the cardiac picture is mixed and entirely preclinical for the fragment ^[5].

Does TB-500 promote angiogenesis and is that a safety concern?

Thymosin beta-4 promotes endothelial migration and new-vessel formation in animal and biomaterial models, which aids repair but also underlies the theoretical tumor-angiogenesis concern, since the same pro-angiogenic activity could in principle support tumor progression ^[10]. It is the clearest example of one mechanism cutting both ways.

Does TB-500 reduce inflammation?

Full-length thymosin beta-4 suppresses NF-κB and IL-8 signaling in vitro and has reduced fibrosis in liver, renal, and pulmonary animal models; recent work links its effects to specialized pro-resolving pathways ^[13]. These are mechanistic and preclinical findings, not human anti-inflammatory claims.

What are the side effects of TB-500?

Human safety data exist only for full-length thymosin beta-4: an intravenous Phase 1 study found it well tolerated to 1260 mg with only infrequent mild or moderate events and no serious adverse events ^[6]. The fragment itself has no characterized human side-effect profile, and a tumor/angiogenesis signal is flagged as a theoretical concern ^[10].

What is the difference between TB-500 and BPC-157?

TB-500 is the synthetic Ac-LKKTETQ fragment of thymosin beta-4 acting through actin sequestration ^[1]; BPC-157 is a separate gastric-derived peptide with a different proposed mechanism. Both are unapproved research peptides studied for tissue repair in animal models ^[10]. They are not the same compound and were not developed from the same protein.

Does TB-500 help wound healing?

In rat full-thickness and corneal-injury models, thymosin beta-4 accelerated re-epithelialization, increased wound contraction, and raised collagen deposition and angiogenesis; as little as ~10 pg stimulated keratinocyte migration ^[3]. Topical human venous-ulcer and dry-eye trials used the full-length protein (RGN-259), not the TB-500 fragment ^[9].

Is TB-500 safe for long-term use?

There are no long-term human safety data for the TB-500 heptapeptide ^[10]. The only controlled human exposure is a 14-day intravenous study of full-length thymosin beta-4 ^[6]. Open questions include the tumor/angiogenesis signal and the uncertain identity and purity of research-grade material ^[10].

Why is TB-500 used in racehorses?

TB-500 was encountered as a designer drug in racehorses, which prompted the first equine LC-MS detection methods (limits of detection around 0.01-0.02 ng/mL) to control its misuse in equine sport ^[10]. Its presence in racing is a doping-control concern, not an approved veterinary indication.

Is TB-500 legal?

TB-500 is not FDA-approved for human use and is classified by FDA as a 503A Category 2 bulk substance, outside FDA's enforcement-discretion policy for compounding ^[16][18]. It is prohibited by the World Anti-Doping Agency and is classified as a prescription medicine in some jurisdictions ^[10]. The full picture is on TB-500 legal status and FDA 503A category.

Can you get TB-500 from a compounding pharmacy?

TB-500 is not an FDA-approved drug, and as a 503A Category 2 substance it is not eligible for routine 503A compounding while that status stands ^[16][18]. The TB-500 legal status and FDA 503A category page describes, in general terms, how lawful compounded access works for this substance class — without naming any pharmacy, clinic, or vendor.

What is the FDA 503A status of TB-500?

FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — bulk substances that may present significant safety risks — effective with its September 29, 2023 nominated-substances update, citing potential immunogenicity for certain routes and a lack of important safety information ^[16]. Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding ^[18].

Is TB-500 a steroid?

No. TB-500 is a peptide fragment — the seven-residue Ac-LKKTETQ sequence from thymosin beta-4 — not a steroid hormone ^[1]. Its proposed mechanism is actin sequestration and cytoskeletal regulation, not androgen-receptor signaling, so it does not belong to the anabolic-steroid class either chemically or pharmacologically.